Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate.

The pharmacogenomics journal - 1 Oct 2015

Jabeen S, Holmboe L, Alnæs G I G, Andersen A M, Hall K S, Kristensen V N

Abstract excerpt

Osteosarcoma patients are commonly treated with high doses of methotrexate (MTX). MTX is an analog of folate, which is essential for DNA synthesis. Genetic polymorphism at single nucleotide can be indicative to the prognostic outcome in patients. Germ-line variants in candidate genes, coding for enzymes active in the metabolism of MTX, were studied in 62 osteosarcoma patients. Patients harboring the GG genotype...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Methotrexate

Share to Methylenetetrahydrofolate Reductase (NADPH2)

Share to Osteosarcoma

Share to Replication Protein C

Share to Tetrahydrofolate Dehydrogenase

Source

Identifiers

PMID: 25778468
DOI: 10.1038/tpj.2015.11

Genes

DHFR
MTHFR
RFC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate.PMID 25778468Read ↗

ABCC2(rs717620), and ABCC3 (rs4793665) affect high dose Methotrexate toxicity, and outcome in children with osteosarcomaSemantic proximity Read ↗

Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcomaSemantic proximity Read ↗

Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.Semantic proximity Read ↗

GENETIC PREDICTORS OF TOXIC EFFECTS OF METHOTREXATE IN CANCER PATIENTS.Semantic proximity Read ↗

The effects of genetic polymorphism on toxicity and pharmacokinetics of methotrexate in Egyptian adult patients with leukaemia or lymphoma.Semantic proximity Read ↗

Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcomaSemantic proximity Read ↗

Correlation between gene polymorphism and adverse reactions of high-dose methotrexate in osteosarcoma patients: a systematic review and meta-analysis.Semantic proximity Read ↗

Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.Semantic proximity Read ↗

Gene polymorphisms in the folate metabolism and their association with MTX-related adverse events in the treatment of ALL.Semantic proximity Read ↗

Pharmacogenetics of methotrexateSemantic proximity Read ↗

Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases.Semantic proximity Read ↗

Influence of Reduced Folate Carrier and Dihydrofolate Reductase Genes on Methotrexate-Induced CytotoxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.